Literature DB >> 989660

The serum half-life of somatomedin activity: evidence for growth hormone dependence.

K L Cohen, S P Nissley.   

Abstract

The serum half-life of somatomedin (SM) activity has been measured following the intravenous injection of SM activity into hypophysectomized rats. A [3H]thymidine incorporation assay in chick embryo fibroblasts (CEFs) has been utilized to measure SM activity. Cell cycle analysis data obtained with the flow microfluorometer shows that the [3H]thymidine incorporation data reflects actual DNA synthesis. When normal rat serum was injected, a half-life for SM activity of approximately 3 h was determined. In marked contrast, when serum from hypophysectomized (hypox) rats acutely treated with growth hormone (GH) was used as the source of SM actively, the half-life of the SM actively was short, approximately 8 min. However, when serum from hypox rats chronically treated with GH was injected, the half-life was again long, approximately 4 h. SM activity has been separated from its binding proteins by boiling under acid conditions or chromatography on Sephadex G-50 in 1 N acetic acid. The half-life of this partially purified SM activity was short, in the range of 10-30 min finally, recombination of the partially purified sm activity with the large proteins in normal serum extended in half-life of the sm from 10-03 min to about 2 h. These data indicate that the serum half-life of SM activity is GH dependent and suggest that the serum binding protein, like SM itself, is under GH control.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 989660     DOI: 10.1530/acta.0.0830243

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  19 in total

Review 1.  The extracellular regulation of growth factor action.

Authors:  R Flaumenhaft; D B Rifkin
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

Review 2.  Molecular biology of the insulin-like growth factors. Relevance to nervous system function.

Authors:  J E Hepler; P K Lund
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

3.  IGFBP-3, a sensitive marker of physical training and overtraining.

Authors:  M Elloumi; N El Elj; M Zaouali; F Maso; E Filaire; Z Tabka; G Lac
Journal:  Br J Sports Med       Date:  2005-09       Impact factor: 13.800

Review 4.  Somatomedins: chemical and functional characteristics of the different molecular forms.

Authors:  A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1989-04       Impact factor: 4.256

5.  Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats.

Authors:  J Zapf; C Hauri; M Waldvogel; E R Froesch
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Plasma binding proteins for platelet-derived growth factor that inhibit its binding to cell-surface receptors.

Authors:  E W Raines; D F Bowen-Pope; R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

7.  Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats.

Authors:  J Zapf; C Hauri; M Waldvogel; E Futo; H Häsler; K Binz; H P Guler; C Schmid; E R Froesch
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

9.  Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma.

Authors:  E Ciccarelli; M R Valetto; E Vasario; T Avataneo; S Grottoli; F Camanni
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

10.  Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children.

Authors:  G Scirè; C Del Bianco; G L Spadoni; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.